

ESMO ADVANCED COURSE

SINGAPORE 4-5 DECEMBER 2023

Co-Chairs

Li-Tzong Chen, Taiwan Arndt Vogel, Germany



ESMO ADVANCED COURSE PROGRAMME

Locoregional and systemic therapy options for advanced HCC patients: Optimising practice and research

Singapore 4-5 December 2023

CO-CHAIRS

Li-Tzong Chen, Taiwan Arndt Vogel, Germany **SPEAKERS**

Chiun Hsu, Taiwan Rachel W.-J. Jeng, Taiwan Masaki Kaibori, Japan Joycelyn J. X. Lee, Singapore Tim Meyer, United Kingdom Maria Reig, Spain

Anna Saborowski, Germany Gonzalo Sapisochin, Canada

LEARNING OBJECTIVES

- To decide between local and systemic therapy or combinations
- To decide about first and second line systemic therapy
- To learn about future targets and clinical trial designs

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org

www.esmo.org



Monday, 4 December 2023

09:00-09:10	Welcome and introduction Li-Tzong-Chen, TW Arndt Vogel, DE
09:10-10:05	Session 1 - Resection and transplantation in HCC Chair: Li-Tzong Chen, TW
20'	Open vs. laparoscopic resections: What needs to be considered Masaki Kaibori, JP
20'	Liver transplantation: How far can we go beyond Milan? Gonzalo Sapisochin, CA
15'	Discussion
10:05-11:20	Session 2 - Intra-arterial therapies Chairs: Arndt Vogel, DE and Tim Meyer, UK
20'	Update on SIRT/Y-90 Joycelyn J. X. Lee, SG
20'	Update on TACE Tim Meyer, UK
20'	Combination of TACE/Y-90 with IO based combinations Maria Reig, ES
15'	Discussion
11:20-11:50	Coffee break
11:20-11:50 11:50-12:45	Coffee break Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW
	Session 3 - Systemic therapies
11:50-12:45	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies
11:50-12:45 20'	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy?
11:50-12:45 20' 20'	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy? Chiun Hsu, TW
11:50-12:45 20' 20' 15'	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy? Chiun Hsu, TW Discussion
11:50-12:45 20' 20' 15' 12:45-13:45	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy? Chiun Hsu, TW Discussion Lunch Session 4 - Precision medicine in HCC
11:50-12:45 20' 20' 15' 12:45-13:45 13:45-14:40	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy? Chiun Hsu, TW Discussion Lunch Session 4 - Precision medicine in HCC Chairs: Joycelyn J. X. Lee, SG and Anna Saborowski, DE Role of next generation sequencing and targeted therapies in HCC
11:50-12:45 20' 20' 15' 12:45-13:45 13:45-14:40 20'	Session 3 - Systemic therapies Chairs: Li-Tzong Chen, TW and Rachel WJ. Jeng, TW Update 1st line therapies Anna Saborowski, DE Update 2nd line therapies: Which 2L treatment after 1L IO-based therapy? Chiun Hsu, TW Discussion Lunch Session 4 - Precision medicine in HCC Chairs: Joycelyn J. X. Lee, SG and Anna Saborowski, DE Role of next generation sequencing and targeted therapies in HCC Arndt Vogel, DE Update on molecular classes and clinical biomarkers in HCC: Does HCC of viral vs. metabolic aetiology respond differently to systemic therapy?

15:10-16:05

Session 5 - Multidisciplinary approach in advanced HCC
Chairs: Arndt Vogel, DE, Maria Reig, ES and Gonzalo Sapisochin, CA

20'
Systemic review of study design and available results
Chiun Hsu, TW

20'
East meets West in practice
Li-Tzong Chen, TW

15'
Discussion

Networking dinner

Tuesday, 5 December 2023

09:00-12:30 Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

25' Introduction based on clinical cases presented by speakers

30' Discussion 5' Break

Workshop 1 Local and systemic therapy or combinations

60' Joycelyn J. X. Lee, SG

Tim Meyer, UK

Gonzalo Sapisochin, CA

Workshop 2 First and second line systemic therapy

60' Li-Tzong Chen, TW Anna Saborowski, DE

Workshop 3 Future targets and clinical trial designs

60' Chiun Hsu, TW

Maria Reig, ES Arndt Vogel, DE

11:00-11:30 Coffee break

11:30-12:30 Workshops continuation

12:30-13:00 Synthesis and wrap-up

Li-Tzong-Chen, TW Arndt Vogel, DE

13:00-14:00 Lunch